70
Participants
Start Date
December 1, 2019
Primary Completion Date
December 31, 2023
Study Completion Date
December 31, 2023
Tolcapone 200 MG
Tolcapone is a brain penetrant catechol-O-methyltransferase (COMT) inhibitor. It will be administered in randomized, double-blind, counterbalanced fashion with a placebo.
Functional Magnetic Resonance Imaging (fMRI)
FMRI provides an indirect and noninvasive measure of brain activity.
University of California, Berkeley, Berkeley
University of California, San Francisco
OTHER
Lawrence Berkeley National Laboratory
UNKNOWN
University of California, Berkeley
OTHER